Literature DB >> 17635498

Add-on therapy with doxazosin in patients with hypertension influences arterial stiffness and albuterol-mediated arterial vasodilation.

Andrzej Wykretowicz1, Przemyslaw Guzik, Tomasz Krauze, Karolina Adamska, Agata Milewska, Henryk Wysocki.   

Abstract

AIMS: Doxazosin is an antihypertensive agent with largely unknown effects on arterial stiffness and vasodilation. The aim of this study was to determine the effect of the addition of doxazosin extended-release (ER) to the standard management of hypertension in patients with inadequately controlled blood pressure (BP) on arterial stiffness and arterial vasodilation.
METHODS: Twenty patients with inadequately controlled hypertension were treated with 4 mg doxazosin ER daily for 16 weeks as an adjunct to their existing antihypertensive regimen.
RESULTS: Doxazosin ER add-on therapy was associated with significantly reduced systolic (P < 0.0001) and diastolic (P = 0.0003) BP, improved arterial stiffness (determined by digital volume pulse analysis (P = 0.048) and albuterol-mediated arterial vasodilation (P = 0.030).
CONCLUSIONS: Add-on therapy with 4 mg of doxazosin ER daily reduces BP and arterial stiffness and improves arterial vasodilation in response to adrenergic stimulation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17635498      PMCID: PMC2198780          DOI: 10.1111/j.1365-2125.2007.02980.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  12 in total

1.  Doxazosin, an inferior antihypertensive agent?

Authors:  C D Furberg
Journal:  J Hum Hypertens       Date:  2002-06       Impact factor: 3.012

Review 2.  Pulse pressure, arterial stiffness, and drug treatment of hypertension.

Authors:  L M Van Bortel; H A Struijker-Boudier; M E Safar
Journal:  Hypertension       Date:  2001-10       Impact factor: 10.190

3.  Photoplethysmographic assessment of pulse wave reflection: blunted response to endothelium-dependent beta2-adrenergic vasodilation in type II diabetes mellitus.

Authors:  P J Chowienczyk; R P Kelly; H MacCallum; S C Millasseau; T L Andersson; R G Gosling; J M Ritter; E E Anggård
Journal:  J Am Coll Cardiol       Date:  1999-12       Impact factor: 24.094

4.  Pulse-wave analysis: clinical evaluation of a noninvasive, widely applicable method for assessing endothelial function.

Authors:  Ian B Wilkinson; Ian R Hall; Helen MacCallum; Isla S Mackenzie; Carmel M McEniery; Bart J van der Arend; Yae-Eun Shu; Laura S MacKay; David J Webb; John R Cockcroft
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-01       Impact factor: 8.311

5.  Doxazosin treatment and peroxidation of low-density lipoprotein among male hypertensive subjects: in vitro and ex vivo studies.

Authors:  I R Brude; C A Drevon; K Viken; J E Arnstad; K N Valnes; M S Nenseter
Journal:  Biochem Pharmacol       Date:  1999-07-01       Impact factor: 5.858

6.  Determination of age-related increases in large artery stiffness by digital pulse contour analysis.

Authors:  S C Millasseau; R P Kelly; J M Ritter; P J Chowienczyk
Journal:  Clin Sci (Lond)       Date:  2002-10       Impact factor: 6.124

Review 7.  Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance?

Authors:  Rhian M Touyz
Journal:  Hypertension       Date:  2004-07-19       Impact factor: 10.190

8.  Effect of doxazosin gastrointestinal therapeutic system on patients with uncontrolled hypertension: the ASOCIA Study.

Authors:  Fernando de Alvaro; Miguel Angel Hernández-Presa
Journal:  J Cardiovasc Pharmacol       Date:  2006-02       Impact factor: 3.105

9.  Doxazosin GITS versus hydrochlorothiazide as add-on therapy in patients with uncontrolled hypertension.

Authors:  Carlos Campo; Julian Segura; Cecilia Roldán; José M Alcázar; José L Rodicio; Luis M Ruilope
Journal:  Blood Press Suppl       Date:  2003-12

10.  Effect of administration and withdrawal of doxazosin on ambulatory blood pressure in patients with essential hypertension.

Authors:  Y Takata; T Yoshizumi; Y Ito; Y Hirota; M Fujishima
Journal:  Angiology       Date:  1995-01       Impact factor: 3.619

View more
  2 in total

Review 1.  Clinical pharmacology--providing tools and expertise for translational medicine.

Authors:  J K Aronson; A Cohen; L D Lewis
Journal:  Br J Clin Pharmacol       Date:  2008-02       Impact factor: 4.335

2.  A randomised, factorial trial to reduce arterial stiffness independently of blood pressure: Proof of concept? The VaSera trial testing dietary nitrate and spironolactone.

Authors:  Charlotte E Mills; Virginia Govoni; Luca Faconti; Maria-Linda Casagrande; Steven V Morant; Hannah Crickmore; Fahad Iqbal; Perry Maskell; Alisha Masani; Elisa Nanino; Andrew J Webb; J Kennedy Cruickshank
Journal:  Br J Clin Pharmacol       Date:  2020-02-22       Impact factor: 4.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.